The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help. The interviews webpage also uses YouTube, where subtitles and translations are generated automatically by AI; please be advised to exercise caution when precise interpretation is required. For further support with YouTube, visit YouTube Help.
What are mutational patterns, and do they affect outcomes of patients with acute myeloid leukemia?
Brian Huntly
August 2, 2022
During the EHA 2022 Congress, Know AML spoke with Brian Huntly, University of Cambridge, Cambridge, UK. We asked, What are mutational patterns, and do they affect outcomes of patients with acute myeloid leukemia (AML)?
Huntly begins by describing how combinations of mutations can lead to leukemia, and the developments we have seen in cytogenetics. Huntly outlines how mutational panels can be used in a prognostic setting, as well as current investigations into novel therapies.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
